Surveillance for Adverse Events following Immunization from 2008 to 2011 in Zhejiang Province, China
Surveillance for Adverse Events following Immunization from 2008 to 2011 in Zhejiang Province, China
复制标题
DOI：
10.1128/cvi.00541-12
复制
发表时间：
2013-02-01
影响因子：
--
通讯作者：
Qi, Xiaohua
中科院分区：
文献类型：
--
作者：
Hu, Yu;Li, Qian;Qi, Xiaohua
本研究总结了浙江省向国家AEFI监测系统(NASS)报告的AEFI被动监测数据，描述了2008-2011年的报告趋势。使用来自个人免疫信息系统和浙江省统计局的分母数据计算AEFI报告率。总共报告了6265份AEFI记录；总体报告率为每10万剂9.2份。报告率出现了两个高峰，这主要与2009年引入大流行性H1N1流感病毒疫苗(PH1N1)和2010年开展麻疹-腮腺炎疫苗运动有关。AEFI中的大多数描述了不严重的事件。有记录的死亡人数为15人，但可能只有1人与免疫有关。最常见的反应是发热和注射部位反应。浙江省分发的疫苗已被证明总体上是安全的。关于AEFI监测的数据为持续报告趋势提供了一个参考点，并说明了NASS数据库作为监测AEFI的监测工具的价值。
This study summarizes passive surveillance data for adverse events following immunization (AEFI) reported to the National AEFI Surveillance System (NASS) in Zhejiang province and describes reporting trends from 2008 to 2011. AEFI reporting rates were calculated using denominator data from the Individual Immunization Information System and the Zhejiang provincial Bureau of Statistics. A total of 6,265 AEFI records were reported; the overall reporting rate was 9.2 per 100,000 doses. There were two peaks of reporting rates, which were associated mainly with the introduction of the pandemic H1N1 influenza virus vaccine (pH1N1) in 2009 and the measles-mumps vaccine (MM) campaign in 2010. The majority of the AEFI described nonserious events. Fifteen deaths were recorded, but only one was possibly related to immunization. The most frequently reported reactions were fever and injection site reaction. Vaccines distributed in Zhejiang province have proven to be generally safe. The data on AEFI surveillance provide a reference point for ongoing reporting of trends and illustrate the value of the NASS database as a surveillance tool for monitoring of AEFI.